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Background: Chronic obstructive pulmonary disease (COPD) is characterized by airway 
remodeling with an accumulation of inﬂ  ammatory cells. There is also increasing evidence that 
metalloproteinases (MMPs) may contribute to the pathogenesis of COPD, but the inﬂ  uence of 
agents that used for the treatment of COPD is not well understood.
Objective: We evaluated whether tiotropium bromide hydrate (TBH), a M3 muscarinic receptor 
antagonist, could inhibit MMP production from lung f ibroblasts (LFs) in response to tumor 
necrosis factor (TNF)-α stimulation.
Methods: LFs were established from normal lung tissues taken from patients with lung tumors. 
LFs (5 × 105 cells/ml) were stimulated with TNF-α in the presence of various concentrations of 
TBH. After 24 h, culture supernatants were obtained and assayed for the levels of MMPs and 
tissue inhibitor of metalloproteinases (TIMPs) by ELISA. The inﬂ  uence of TBH on mRNA 
expression of MMPs and TIMPs in 4 h-cultured cells was also examined by real-time RT-PCR. 
Furthermore, nuclear factor-κB (NF-κB) and activator protein-1 (AP-1) in LFs treated with 
TBH for 4 h was examined by ELISA.
Results: TBH at more than 15 pg/ml inhibited the production of MMP-2 from LFs after TNF-α 
stimulation, whereas TIMP-1 and TIMP-2 production was scarcely affected by TBH through 
the suppression of both mRNA expression and transcription factor, NF-κB, activation in LFs 
induced by TNF-α stimulation.
Conclusion: These results suggest that the attenuating effect of TBH on MMP-2 production 
from LFs induced by inﬂ  ammatory stimulation may be additional benef icial therapeutic effects 
not directly relating to its bronchodilatory effects.
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Introduction
Chronic obstructive pulmonary disease (COPD) is well accepted to be attributed to 
long-term exposure to toxic gases and particles, most often related to cigarette smoking. 
Histological observations of lung tissues of patients with COPD revealed the presence 
of the airway remodeling with the inf lammatory responses (Hamid et al 2004; Hogg 
et al 2004; Jeffery 2004).
Matrix metalloproteinases (MMPs) are a large family of Zn2+ and Ca2+ dependent 
proteolytic enzymes, which are secreted by a wide variety of cells (eg, inﬂ  ammatory 
cells, epithelial cells, and ﬁ  broblasts, etc) and essential for tissue remodeling, and have 
the ability to degrade various components of the extracellular matrix and basement 
membrane (Murphy et al 1992; Herouy et al 2001). They are accepted to be implicated 
in normal physiological tissue remodeling, inf  lammation, and tumor spread. It is 
widely recognized that many MMPs are expressed in the human lungs, and there is 
compelling evidence linking MMPs to small airway tissue remodeling, which is the 
most important histological ﬁ  nding of COPD (Ohnishi et al 1998; Demedts et al 2005; International Journal of COPD 2008:3(4) 782
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Lagente et al 2005; Baraldo et al 2007). It is also reported 
that levels of MMPs in both lung tissues and bronchoalveolar 
lavage ﬂ  uids, including sputum, increase as lung function 
worsens and the degree of airway remodeling increases 
(Cataldo et al 2000; Kang et al 2003; Babusyte et al 2007). 
Although these reports may suggest that MMPs seem to be 
good candidates for possible therapeutic targets in the COPD 
treatment, there is little evidence showing the inﬂ  uence of 
the agents that used for COPD treatment on MMPs.
Tiotropium bromide hydrate (TBH), the f  irst choice 
agent in the treatment of COPD (Rodrigo et al 2007), is a 
once-daily inhaled anticholinergic bronchodilator, which 
binds to muscarinic receptor subtypes (M1, M2, and M3), 
and exhibits a long duration of action due to prolonged M3 
receptor antagonism (Disse 2001). There is much evidence 
that long-term administration of TBH improves the clinical 
status of COPD patients (Casaburi et al 2002; Vincken et al 
2002; Dusser et al 2006). Although experimental evidence 
showed that TBH could protect airway smooth muscle 
remodeling, which is observed in COPD and asthma (Hamid 
et al 2004; Gosens et al 2005), the inﬂ  uence of TBH on the 
production of MMP, which is the most important enzymes 
for remodeling, is not fully understood. In the present study, 
therefore, we examined the inﬂ  uence of TBH on MMPs 
production from lung f ibroblasts in vitro.
Materials and methods
Agent
TBH was extracted from inhalable powders for therapeutic 
use that contained 22.5 μg TBH and 32.5 μg lactose. The 
powder was dissolved in RPMI-1640 medium supplemented 
with 10% fetal bovine serum (RPMI-FCS) in a volume of 
5.0 ml. This solution was then sterilized by passing through 
0.2 μm ﬁ  lters and stored at 4 °C as a stock solution until used. 
All dilutions used in this study were prepared from this stock 
solution by diluting with RPMI-FCS. To use the medium for 
control, 32.5 μg lactose (Sigma Chemicals, Co., Ltd, St Louis, 
MO, USA) was dissolved in 5.0 ml RPMI-FCS, sterilized, 
diluted with RPMI-FCS in a similar manner. Recombinant 
TNF-α (preservative-free) was purchased from Chemicon 
International, Inc. (Temecula, CA, USA) and diluted with 
RPMI-FCS to give a concentration of 50.0 ng/ml.
Cell source and induction of f ibroblasts
Tissue samples from patients without lung fibrosis or 
COPD were obtained from healthy tissue area during 
pneumonectomy for tumor resection from a tumor-free area. 
All donors (3 female, 43–71 years; 2 male, 41 and 71 years) 
were given a written informed consent, which was approved 
by the Ethics Committee of Showa University. The diced tis-
sue specimens (approximately 1 mm2) were plated at a density 
of 10 pieces in 100 mm tissue culture dishes and covered 
with a cover slip adhered to the dishes. The dishes were then 
placed in a humidif  ied atmosphere containing 5% CO2 at 
37 °C. When a monolayer of f ibroblast-like cells was found 
to be conﬂ  uent, the explanted tissues were removed. The 
cells were then trypsinized, and replated at a concentration of 
5 × 105 cells/ml into 100 mm tissue culture dishes with a f inal 
volume of 10.0 ml. Subsequently, the cells were split 1:2 at 
conﬂ  uence and passaged (Suzaki et al 2003). The cells were 
characterized with antibodies against vimentine, cytokeratin 
and f ibronectine, using ﬂ  uorescent microscopy (Model No. 
IX 70, OLYMPAS Co., Ltd, Tokyo, Japan; Suzaki et al 
2003), and the f  ibroblast purity was more than 99% and 
used as lung-derived f ibroblasts (LFs). LFs at six to seven 
passages were used for the following experiments.
Cell culture
LFs were washed several times with RPMI-FCS, introduced 
into each well of 24-well culture plates in triplicate at a con-
centration of  5 × 105 cells/ml in a volume of 1.0 ml. The cells 
were stimulated with 25.0 ng/ml TNF-α in the presence of 
various concentrations of TBH in a f inal volume of 2.0 ml. 
After 24 h, the culture supernatants were removed, and stored 
at –40 °C until used. In cases of examining transcription 
factor activation and mRNA expression, cells were cultured 
in a similar manner for 4 h and stored at –80 °C until used. 
In all cases, TBH was added to cell cultures 2 h before the 
stimulation with TNF-α.
Assay for MMP and TIMP
MMP-2, MMP-9, TIMP-1, and TIMP-2 levels in culture 
supernatants were assayed using commercially avail-
able human MMP and TIMP ELISA test kits (Amersham 
Biosciences, Bucks, UK) according to the manufacturer’s rec-
ommendation. The results are expressed as the mean ng/ml ± 
standard error (SE) of duplicate assays for f  ive subjects. 
The minimum detectable levels of these ELISA kits were 
0.37 ng/ml for MMP-2, 0.6 ng/ml for MMP-9, 40.0 ng/ml 
for TIMP-1, and 3.0 ng/ml for TIMP-2, respectively.
Real-time polymerase chain 
reaction (PCR)
mRNA was extracted from f ibroblasts using μMACS mRNA 
isolation kits (Milteny Biotec GmbH, Bergisch Gladbach, 
Germany) according to the manufacturer’s instructions. International Journal of COPD 2008:3(4) 783
Suppression of MMP production by tiotropium in vitro
The f irst-strand cDNA synthesis from 1.0 μg mRNA was 
performed using the SuperScript Preamplif ication System for 
cDNA synthesis (GIBCO BRL, Gaithersburg, MD, USA). 
PCR was then carried out using a GeneAmp 5700 Sequence 
Detection System (Applied Biosystems, Foster City, CA, 
USA). PCR mixture consisted of 2.0 μl of sample cDNA 
solution (10.0 ng/μl), 25.0 μl of SYBR-Green Mastermix 
(Applied Biosystems), 0.3 μl of both sense and antisense 
primers, and distilled water to give a f inal volume of 50 μl. 
The reaction was conducted as follows: 4 min at 95 °C, fol-
lowed by 40 cycles of 15 sec at 95 °C and 60 sec at 60 °C. 
β-actin was amplif ied as an internal control. mRNA levels 
were calculated by using the comparative parameter thresh-
old cycle (Ct) and normalized to β-actin. Oligonucleotide 
sequences of the primers used were shown in Table 1.
Assay for NF-κB and AP-1 activities
NF-κB activity was analyzed with commercially available 
ELISA test kits (Active Motif Co. Ltd., Carlsbad, CA, USA) 
that contained suff icient reagents and monoclonal antibod-
ies against p50 and p65, according to the manufacturer’s 
recommended procedure. In brief, nuclear extract (5.0 μg 
protein) from LFs was introduced into each well of 96-well 
microtiter plates pre-coated with oligonucleotide contain-
ing the NF-κB consensus site (5′-GGGACTTTCC-3′) in 
a volume of 20.0 μl, and incubated for 1 h at 25 °C. After 
washing three times, 100 μl of monoclonal antibody against 
p50 or p65 was added to the appropriate wells, and incu-
bated for a further 1 h at 25 °C. Anti-IgG HRP-conjugate 
in a volume of 100 μl was then added and incubated 1 h at 
25 °C. Absorbance at 450 nm was measured after the addi-
tion of tetramethylbenzine solution. AP-1 activity was also 
examined using a commercially available ELISA test kit 
(Active Motif, Co., Ltd), which contains suff icient reagents 
and monoclonal antibodies against Fra 2 and Jun B, according 
to the manufacturer’s instructions. Using the manufacturer’s 
data sheet, the amount of NF-κB and AP-1, bound to DNA 
can be measured by these two ELISA systems.
Statistical analysis
The statistical signiﬁ  cance of the difference between the 
control and experimental data was analyzed using ANOVA 
followed by Fisher’s PLSD test. A p value  0.05 was 
accepted as statistically signiﬁ  cant.
Results
Inﬂ  uence of   TBH on MMP-2, MMP-9, 
TIMP-1, and TIMP-2 production from LFs
The f irst set of experiments was undertaken to examine the 
inﬂ  uence of TBH on MMPs production from LFs in response 
to TNF-α stimulation. LFs (5 × 105 cells/ml) was stimulated 
with 25.0 ng/ml TNF-α in the presence of 0, 5, 15, 20, 25, or 
50 pg/ml TBH for 24 h. MMPs levels in culture supernatants 
were assayed by ELISA. As shown in Figure 1, TBH sup-
pressed MMP-2 production from LFs, which is enhanced by 
TNF-α stimulation. The minimum concentration of the agent, 
which caused signiﬁ  cant suppression of MMP-2 production 
Table 1 Primer sequences used for real-time polymerase chain reaction
Primer sequences Position Product size, bp
MMP-2
Sense 5′-AGATCTTCTTCTTCAAGGACCGGTT-3′ 1740–1764
Antisense 5′-GGCTGGTCAGTGGCTTGGGGTA-3′ 1964–1943 440
MMP-9
Sense 5′-TGGACGATGCCTGCAACGTG-3′ 1554–1573
Antisense 5′-GTCGTGCGTGTCCAAAGGCA-3′ 2008–1986 454
TIMP-1
Sense 5′-CACCCACAGACGGCCTTCTGCAAT-3′ 150–173
Antisense 5′-AGTGTAGGTCTTGGTGAAGCC-3′ 494–474 345
TIMP-2
Sense 5′-CTCGCTGGACGTTGGAGGAAAGAA-3′ 602–625
Antisense 5′-AGCCCATCTGGTACCTGTGGTTCA-3′ 756–733 433
-actin
Sense 5′-ACCCACACTGTGCCCATCTA-3′ 551–570
Antisense 5′-CGGAACCGCTCATTGCC-3′ 733–717 239International Journal of COPD 2008:3(4) 784
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was 15 pg/ml. On the other hand, TNF-α stimulation could 
not induce MMP-9 production from LF; culture supernatants 
contained undetectable levels (0.6 ng/ml) of MMP-9 by 
ELISA (data not shown). We next examined the inﬂ  uence 
of   TBH on the production of both TIMP-1 and TIMP-2 
from LFs in response to TNF-α stimulation. As shown in 
Figures 2a and b, TBH could not suppress the ability of 
LFs to produce TIMP-1 and TIMP-2 from LFs, even when 
50 pg/ml of the agent was added to cell cultures.
Inﬂ  uence of   TBH on MMP and TIMP 
mRNA expression in LFs
The second set of experiments was undertaken to examine the 
inﬂ  uence of  TBH on mRNA expression for MMP-2, TIMP-1, 
and TIMP-2 in LFs. LFs (5 × 105 cells/ml) were stimulated with 
25.0 ng/ml TNF-α in the presence of 0, 5, 15, 20, or 25 pg/ml 
TBH for 4 h. Levels of mRNA expression were evaluated by 
real-time PCR. Addition of  TBH at more than 15 pg/ml into 
cell cultures signif icantly suppressed MMP-2 mRNA expres-
sion in LFs (Figure 3). However, TBH could not reduce levels 
of TIMP mRNA expression in LFs (Figures 4a and b).
Inﬂ  uence of   TBH on transcription factor 
activation in LFs
The third set of experiments was designed to examine the 
inﬂ  uence of TBH on transcription factor, NF-κB and AP-1, 
activation in LFs. LFs (5 × 105 cells/ml) were stimulated 
with 25.0 ng/ml TNF-α in the presence of 0, 5, 15, 20, 25, 
or 50 pg/ml TBH for 4 h. The nuclear extract was prepared, 
and NF-κB activity was assessed by measuring p50 and p65 
activities by ELISA. As shown in Figure 5, addition of TBH 
at more than 15 pg/ml caused signiﬁ  cant suppression of p50 
and p65 activation in LF, which was induced by TNF-α 
stimulation. On the other hand, TBH could not suppress 
TNF-α stimulated AP-1 activation, as assessed by both Fra-2 
and Jun B activities (Figure 6), even when 50.0 ng/ml of the 
agent was added to cell cultures.
Discussion
The present results clearly demonstrated that TBH at more 
than 15 pg/ml could suppress the production of  MMP-2 from 
LFs with virtually no effect on the production of TIMP-1 
and TIMP-2. In addition, this inhibitory action of TBH on 
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Figure 1 Inﬂ  uence of tiotropium on metalloproteinase (MMP)-2 production from lung f ibroblasts induced by tumor necrosis factor (TNF)-α stimulation.  Cells (5 × 105 cells/ml) 
were stimulated with 25.0 ng/ml TNF-α in the presence of various concentrations of tiotropium for 24 h. MMP-2 levels in culture supernatants were examined by ELISA. Data 
are expressed as the mean ng/ml + SE of f ive different subjects.
Notes: *signiﬁ  cant (P  0.05) as compared with TNF alone.International Journal of COPD 2008:3(4) 785
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Figure 2 Inﬂ  uence of tiotropium on the production of tissue inhibitor of metalloproteinase (TIMP)-1 (a) and TIMP-2 (b) from lung ﬁ  broblasts in response to tumor necrosis 
factor (TNF)-α stimulation. Cells (5 × 105 cells/ml) were stimulated with 25.0 ng/ml TNF-α in the presence of various concentrations of tiotropium for 24 h.   TIMP-1 and 
TIMP-2 levels in culture supernatants were examined by ELISA. Data are expressed as the mean ng/ml + SE of ﬁ  ve different subjects.
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Figure 3 Inﬂ  uence of tiotropuim on matrix metalloproteinase (MMP)-2 mRNA expression in lung ﬁ  broblasts after tumor necrosis factor (TNF)-α stimulation. Cells  (5 × 105 
cells/ml) were stimulated with 25.0 ng/ml TNF-α in the presence of various concentrations of tiotropium for 4h. mRNA expression was examined by real-time RT-PCR. Data 
are expressed as the mean ratio + SE of ﬁ  ve different subjects.
Notes: *signiﬁ  cant (P  0.05) as compared with TNF alone.International Journal of COPD 2008:3(4) 786
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Figure 5 Inﬂ  uence of tiotropium on nuclear factor (NF)-κB activation in lung ﬁ  broblasts induced by tumor necrosis factor (TNF)-α stimulation. Cells (5 × 105 cells/ml) were 
stimulated with 25.0 ng/ml TNF-α in the presence of various concentrations of tiotropium for 4 h. NF-κB, p-50 and p-65, activities were assayed by ELISA. Data are expressed 
as the mean optical density (OD) at 450 nm + SE of ﬁ  ve different subjects.
Notes: *signiﬁ  cant (P  0.05) as compared with TNF alone.
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Figure 4 Inﬂ  uence of tiotropium on mRNA expression for tissue inhibitor of metalloproteinases (TIMP)-1 (a) and TIMP-2 (b) in lung ﬁ  broblasts in response to tumor necrosis 
factor (TNF)-α stimulation. Cells (5 × 105 cells/ml) were stimulated with 25.0 ng/ml TNF-α in the presence of various concentrations of tiotropium for 4 h. mRNA expression 
was examined by real-time RT-PCR. Data are expressed as the mean ratio + SE of ﬁ  ve different subjects.
MMP production is due, in part, to its suppressive effect on 
MMP mRNA expression through the inhibition of transcrip-
tion factor NF-κB activation by TNF-α stimulation. After 
oral inhalation of TBH, plasma drug levels was gradually 
increased, plateued at 16 ng/ml when COPD patient was 
treated with 18.0 μg TBH for 2–3 weeks (Keam et al 2004), 
suggesting that suppression of MMP-2 production may be 
occurred in both airways and peripheral lung tissues of TBH-
treated COPD patients.
COPD is a chronic lung disease, which is mainly induced 
by inhalation of cigarette smoke, resulting in irrevers-
ible airway limitation. A common feature of the disease International Journal of COPD 2008:3(4) 787
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is the chronic inflammation with intense infiltration of 
inﬂ  ammatory cells, especially neutrophils, macrophages and 
T cells in the airways and lungs (Hamid et al 2004; Hogg et al 
2004; Jeffery 2004). Histological observation also revealed 
structural abnormalities, including thickening of the basement 
membrane, structural ﬁ  brosis and mucous gland hyperplasia 
(Hamid et al 2004; Hogg et al 2004; Jeffery 2004). These 
cellular events are now called tissue remodeling, and are 
involved in an extensive alteration of ECM, which is essential 
for supporting normal lung functions (Elkington et al 2006). 
It is also reported that, in some cases of COPD, this tissue 
remodeling causes destruction of healthy lung tissue, lead-
ing to emphysema (Demedts et al 2005). Consideration of 
the biochemistry of the lung matrix predicts that the MMP 
family of enzymes is likely to be involved in this pathology 
(Demedts et al 2005; Elkington et al 2005; Lagente et al 2005; 
Babusyte et al 2007; Lowrey et al 2008). MMPs are a family 
of  Ca2+-activated, Zn2+-dependent proteases that can degrade 
various components of the ECM and basement membrane. 
MMPs are classiﬁ  ed on the basis of substrate speciﬁ  city into 
collagens (MMP-1, and -8), gelatinase (MMP-2 and -9), and 
elastases (MMP-7 and -12), among others (Elkington et al 
2005; Lagente et al 2005). In an analysis of MMPs expression 
in COPD, MMP-1, -2, -8, and -9 were found to be upregulated 
(Segura-Valdez et al 2000; Baraldo et al 2007; Lowrey et al 
2008). Immunohistochemical analysis has also demonstrated 
increased MMP-14 expression in emphysematous lung 
tissues (Ohnishi et al 1998). Furthermore, the studies combin-
ing ELISA, immunocytochemistry and a collagen degradation 
assay revealed the increased levels of MMP-1 and -12 in 
patients with COPD (Imai et al 2001). From these reports, 
it is possible that the attenuating effect of TBH on MMP-2 
production from LFs induced by TNF-α stimulation may be 
additional beneﬁ  cial therapeutic effects not directly relating 
to its bronchodilatory effects. The extracellular activity of 
MMPs is regulated by TIMPs that form an 1:1 complex with 
MMPs (Nagase 1997). The present results clearly showed 
that TBH could not inhibit the TIMP-1 and -2 production 
from LFs after TNF-α stimulation, suggesting that MMP-2 
secreted in small amounts from LFs during TBH treatment are 
inactivated by TIMPs, and resulting in modiﬁ  cation of clinical 
symptoms derived from ECM remodeling and accumulation 
of inﬂ  ammatory cells in COPD.
Although the present results clearly showed the suppres-
sive effect of TBH on MMP production from LFs induced 
by TNF-α stimulation, the mechanisms by which TBH 
could suppress MMP production are not well understood. 
TNF-α is a multifunctional cytokine that plays a role in 
inﬂ  ammation, immunity and a variety of diseases. It is also 
reported that binding of TNF-α to the type-1 TNF receptor 
causes an increase in intracellular Ca2+ concentration through 
calcium inﬂ  ux (Lazaar et al 1998), and results in activation of 
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NF-κB, which are essential transcription factors for MMP-2 
production (Wasylyk et al 1991; Sato et al 1993; Okamoto 
et al 1994). Solifenacin succinate, a newly developed mus-
carinic receptor antagonist, could inhibit carbachol-induced 
intracellular Ca2+ mobilization in guinea pig smooth muscle 
cells and murine submandibular gland cells in vitro (Ikeda 
et al 2002). Soliferan succinate and the other antimuscarinic 
drugs, such as darifenacin and oxybutynin chloride, which 
have higher afﬁ  nity for muscarinic M3 receptor, are also 
reported to inhibit increase in intracellular Ca2+ levels in rat 
salivary gland cells induced by carbachol stimulation (Ohtake 
et al 2004). Furthermore, otilonium bromide, a muscarinic 
receptor antagonist, could inhibit the increase in intracellular 
calcium levels in cells from rat colon by blocking L-type 
calcium channel (Martin et al 2004). Judging from these 
reports, it is possible that addition of TBH into LFs cultures 
caused inhibition of Ca2+ mobilization induced by TNF-α 
stimulation, and resulted in suppression of MMP-2 produc-
tion through the inhibition of transcription factor, especially 
NF-κB, activation. On the other hand, TNF-α-induced gene 
transcription in many cell types is mediated by a number 
of signal transduction pathways, including those involving 
extracellular signal-regulated kinase (ERK), mitogen acti-
vated protein-kinase (MAPK), Jun N-terminal kinase (JUN), 
NF-κB and AP-1 (Turner et al 2005). In these pathways, 
activation of ERK and MAPK is essential for TNF-α-medi-
ated MMP gene expression in fibroblasts after TNF-α 
stimulation (Barchowsky et al 2000; Domeij et al 2002; 
Nee et al 2007). From these reports and the present results 
showing that the inhibitory action of TBH on the NF-κB 
activation may suggest that TBH inhibits ERK and MPK 
activation and results in suppression of MMP production in 
LFs after TNF-α stimulation. This speculation may be sup-
ported, in part, by the observation that muscarinic receptor 
antagonists could prevent inﬂ  ammatory protein production 
induced by acetylcholine stimulation through the inhibition 
of ERK-NF-κB activation (Proﬁ  ta et al 2008). In addition to 
the above mentioned signal transduction pathways, TNF-α 
stimulation causes RhoA/Rho kinase activation, which is 
responsible for the production of MMP-9 and transmem-
brane metalloproteinase, MT1-MMP (Meriane et al 2006), 
through enhancement of JNK activation in endothelial cells 
after TNF-α stimulation (Hunter et al 2006; Mong et al 
2008). It is also reported that AP-1 up-regulation induced 
by TNF-α simulation requires JNK activation (Ventura 
et al 2003; Mong et al 2008). From these reports, there is 
a possibility that TBH may directly inhibit up-regulation 
of RhoA/Rho kinase induced by TNF-α stimulation in LFs 
and results in suppression of MMP-2 production, since TBH 
could not suppress AP-1 activation by TNF-α stimulation 
in LFs. Anyway, further experiments are required to clarify 
the mechanisms by which TBH inhibits MMP-2 production 
from LFs in response to TNF-α stimulation.
Different from MMPs, PEA3, a protooncogene-related 
transcriptional factor, is involved in the regulation of TIMP 
transcription (De Clerk et al 1994; Sato et al 2002). From 
these reports, the present results may be interpreted that TBH 
could not inhibit PEA3 activation by TNF-α stimulation and 
results in negative suppressive effects on TIMP production 
from LFs.
MMPs are produced by numerous cell types, includ-
ing ﬁ  broblast, macrophages and neutrophils in response 
to inﬂ  ammatory stimulation, and mediated transmigration 
of the inﬂ  ammatory cells through the basement membrane 
to propagate inﬂ  ammation (Hoshino et al 1998; Herouy 
et al 2001). MMPs are also responsible for microvascular 
permeability leading to oedema and enhanced inﬂ  amma-
tory cell migration (Hoshino et al 1998; Herouy et al 2001), 
suggesting that administration of TBH into COPD patients 
attenuates inﬂ  ammatory responses in the airways and lungs, 
and may result in favorable modiﬁ  cation of clinical status 
of COPD, including exacerbation frequency. However, a 
recent report showed that TBH therapy for one year could 
not reduce the levels of inﬂ  ammatory makers, such as IL-6, 
IL-8, and myeloperoxidase in sputum from COPD patient as 
compared with placebo-treated patients (Powrie et al 2007). 
The reasons for this discrepancy are not clear at present. TBH 
is well accepted to be able to potentially inhibit cholinergic 
stimulation of mucus-secreting goblet cells in the airways 
to cause reduction in total volume of sputum, resulting in 
increase in protein levels in sputum. This may be responsible 
for negative suppressive effect of TBH on inﬂ  ammatory 
marker levels in sputum.
Finally, this is the ﬁ  rst report showing that TBH exerts 
suppressive effect on MMP production from lung ﬁ  broblasts 
induced by an inﬂ  ammatory stimulation, and this suppres-
sive activity of TBH may be additional beneﬁ  cial effects 
not directly relating to its bronchodilatory effects in COPD 
patients.
Disclosure
The authors report no conﬂ  icts of interest in this work.
References
Babusyte A, Stravinskaite K, Jeroch J, et al. 2007. Patterns of airway 
inﬂ  ammation and MMP-12 expression in smokers and ex-smokers 
with COPD. Respir Res, 8:81–9.International Journal of COPD 2008:3(4) 789
Suppression of MMP production by tiotropium in vitro
Baraldo S, Bazzan E, Zanin ME, et al. 2007. Matrix metalloproteinase-2 
protein in lung periphery is related to COPD progression. Chest, 
132:1733–40.
Barchowsky A, Frleta D, Vincenti MP. 2000. Intergration of the NF-kappaB 
and mitogen-activated protein kinase/AP-1 pathway at the collagenase-1 
promotor: divergence of IL-1 and TNF-dependent signal transduction 
in rabbit primary synovial ﬁ  broblasts. Cytokine, 12:1469–79.
Casaburi R, Mahler DA, Jones PW, et al. 2002. A long-term evaluation of 
once-daily inhaled tiotropium in chronic obstructive pulmonary disease. 
Eur Respir J, 19:205–6.
Cataldo D, Munaut C, Noel A, et al. 2000. MMP-2- and MMP-9-linked 
gelatinolytic activity in the sputum from patients with asthma and 
chronic obstructive pulmonary disease. Int Arch Allergy Immunol, 
123:259–67.
Demedts IK, Brusselle GG, Bracke KR, et al. 2005. Matrix metalloprotein-
ases in asthma and COPD. Current Opinion Pharmacol, 5:257–63.
De Clark YA, Darville MI, Eeckhout Y, et al. 1994. Characterization 
of the promotor of the gene encoding human tissue inhibitor of 
metalloproteinase-2 (TIMP-2). Gene, 139:185–91.
Domaij H, Yucel-Lindberg T, Modeer T. 2002. Signal pathways involved 
in the production of MMP-1 and MMP-3 in human gingival ﬁ  broblasts. 
Eur J Oral Sci, 110:302–6.
Disse B. 2001. Antimuscarinic treatment for lung diseases from research 
to clinical practice. Life Sci, 68:2557–64.
Dusser D, Bravo ML, Iacono P. 2006. The effect of tiotropium on exacerba-
tions and airﬂ  ow in patients with COPD. Eur Respir J, 27:547–55.
Elkington PTG, Friedland JS. Matrix metalloproteinases in destructive 
pulmonary pathology. Thorax, 61:259–66.
Gosens R, Bos IS, Zaagsma J, et al. 2005. Protective effects of tiotropium 
bromide in the progression of airway smooth muscle remodeling. 
Am J Respir Crit Care Med, 171:1096–102.
Hamid Q, Cosio M, Lim S. 2004. Inflammation and remodeling in 
chronic obstructive pulmonary diseases. J Allergy Clin Immunol, 
114:1479–81.
Herouy Y, Mellos P, Bandemir E, et al. 2001. Inﬂ  ammation in stasis 
dermatitis upregulates MMP-1, MMP-2, and MMP-13 expression. 
J Dermatol Sci, 25:198–205.
Hogg JC, Chu F, Utokaparch S, et al. 2004. The nature of small-airway 
obstruction in chronic obstructive pulmonary disease. N Engl J Med, 
350:2645–53.
Hoshino M, Nakamura Y, Sim JJ, et al. 1998. Bronchial subepithelial ﬁ  bro-
sis and expression of matrix metalloproteinase-9 in asthmatic airway 
inﬂ  ammation. J Allergy Clin Immunol, 102:783–8.
Hunter I, Nixon GF. 2006. Spatial compartmentalization of tumor necrosis 
factor (TNF) receptor 1-dependent signaling pathways in human air-
way smooth muscle cells: lipid rafts are essential for TNF-α-mediated 
activation of RhoA but dispensable for the activation of the NF-κB and 
MAPK pathways. J Biol Chem, 281:34705–15.
Ikeda K, Kobayashi S, Suzuki M, et al. 2002. M3 receptor antagonism by the 
novel antimuscarinic agent solifenacin in the urinary bladder and sali-
vary gland. Naunyn Schmiedebergs Arch Pharmacol, 366:97–103.
Imai K, Dalal SS, Chen ES, et al. 2001. Human collagenase (matrix 
metalloproteinase-1) expression in the lungs of patients with emphy-
sema. Am J Respir Crit Care Med, 163:786–91.
Jeffery PK. 2004. Remodeling and inﬂ  ammation of bronchi in asthma 
and chronic obstructive pulmonary disease. Proc Am Thorac Soc, 
1:176–83.
Kang MJ, Oh YM, Lee JC, et al. 2003. Lung matrix metalloproteinase-9 
correlates with cigarette smoking and obstruction of airﬂ  ow. J Korean 
Med Sci, 18:821–7.
Keam SJ, Keating GM. 2004. Tiotropium bromide. A review of its use as main-
tenance therapy in patients with COPD. Treat Respir Med, 3:247–68.
Lagente V, Manoury B, Nenan S, et  al. 2005. Role of matrix 
metalloproteinases in the development of airway inﬂ  ammation and 
remodeling. Braz J Med Biol Re, 38:1521–30.
Lazaar AL, Amrani Y, Hsu J, et al. 1998. CD40-mediated signal transduction 
in human airway amooth muscle. J Immunol, 161:3120–7.
Lowrey G, Henderson N, Blakey JD, et al. 2008. MMP-9 protein level does 
not reﬂ  ect overall MMP activity in the airways of patients with COPD. 
Respir Med, 102:845–51.
Martin MT, Hove-Madsen L, Jimenz M. 2004. Otilonium bromide inhib-
its muscle contractions via L-type calcium channels in the rat colon. 
Neurogastroenterol Motil, 16:175–83.
Meriane M, Duhamel S, Lejeune L, et al. 2006. Cooperation of matrix 
metalloproteinases with the RhoA/Rho kinase and mitogen-activated 
protein kinase: Kinase-1/extracellular signal-regulated kinase signaling 
pathways is required for the shingosine-1-phosphate-induced mobiliza-
tion of marrow-derived stroma cells. Stem Cells, 24:2557–65.
Murphy G, Docherty AJ. 1992. The matrix metalloproteinases and their 
inhibitors. Am J Respir Cell Mol Biol, 7:120–5.
Mong PY, Petrulio C, Kaufman HL, et al. 2008. Activation of Rho Kinase 
by TNF-α is required for JNK activation in human pulmonary micro-
vascular endothelial cells. J Immunol, 180:550–8.
Nagase H. 1997. Activation mechanisms of matrix metalloproteinase. Biol 
Chem, 378:151–60.
Nee L, Tuite N, Ryan MP, et al. 2007. TNF-alpha and IL-1 beta-mediated 
regulation of MMP-9 and TIMP-1 in human glomelular mesangial cells. 
Nephron Exp Nephrol, 107:73–86.
Ohnishi K, Takagi M, Kurokawa Y, et al. 1998. Matrix-metalloproteinase-
mediated extracellular matrix protein degradation in human pulmonary 
emphysema. Lab Invest, 78:1077–87.
Ohtake A, Ukai M, Hatanaka T, et al. 2004. In vitro and in vivo tissue 
selectivity proﬁ  le of solifenacin succinate (YM905) for urinary bladder 
over salivary gland in rats. Eur J Pharmacol, 492:243–50.
Okamoto SI, Mukaida N, Yasumoto K, et al. 1994. The interleukin-8, AP-1 
and kB-like sites are genetic end targets of FK-506-sensitive pathway 
accompanied by calcium mobilization. J Biol Chem, 269:8582–9.
Powrie DJ, Wilkinson TMA, Donaldson GC, et al. 2007. Effect of tiotro-
pium on sputum and serum inﬂ  ammatory markers and exacerbation in 
COPD. Eur Res J, 30:472–8.
Proﬁ  ta M, Bonanno A, Siena L, et al. 2008. Acetylcholine mediates the 
release of IL-9 in human bronchial epithelial cells by a NFκB/ERK-
dependent mechanism. Eur J Pahrmacol, 582:145–53.
Rodrigo GJ, Nannini LJ. 2007. Tiotropium for the treatment of stable chronic 
obstructive pulmonary diseases: a systemic review with meta-analysis. 
Pulm Pharmacol Ther, 20:495–502.
Sato H, Seiki M. 1993. Regulation of 92 kDa type IV collagenase gene 
expression which is associated with invasiveness of tumor cells. 
Oncogene, 8:395–405.
Sato T, Koike L, Miyata Y, et al. 2002. Inhibition of activator protein-1 
binding activity and phosphatidylinositol 3-kinase pathway by a 
polymethoxy ﬂ  avonoid, results in augmentation of tissue inhibitor 
of mettaloproteinase-2 production and suppression of production of 
matrix metalloproteinases-2 and -9 in human ﬁ  brosarcoma HT-1080 
cells. Cancer Res, 62:1025–9.
Segura-Valdez L, Pardo A, Gaxiola M, et al. 2000. Upregulation of elatinases 
A and B, collagenases 1 and 2, and increased parenchymal cell death 
in COPD. Chest, 117:684–94.
Suzaki H, Asano K, Yu M, et al. 2003. Inﬂ  uence of roxithromycin on inﬂ  am-
matory cytokine production from nasal polyp ﬁ  broblasts in vitro. Acta 
Otolaryngol, 123:637–42.
Turner NA, O’Regan DJ, Ball SG, et al. 2005. Simvastatin inhibits MMP-9 
secretion from human saphenous vein smooth muscle cells by inhibit-
ing the Rho/ROCK pathway and reducing MMP-9 mRNA levels. 
FASB J, 19:804–6.
Vincken W, Van Noord JA, Greefhorst AP, et al. 2002. Improved health 
outcomes in patients with COPD during 1yr’s treatment with tiotropium. 
Eur Respir J, 19:217–24.
Ventura JJ, Kennedy NJ, Lamb JA, et al. 2003. c-Jun NH2-terminal kinase 
is essential for the regulation of AP-1 by tumor necrosis factor. Med. 
Cell Biol, 23:2871–82.
Wasylyk C, Gutman A, Nicholson R, et al. 1991. The c-Ets oncoprotein 
activates the stromelysin prompter through the same elements as several 
non-nuclear oncoprotein. EMBO J, 10:1127–34.